AstraZeneca

JCR Pharmaceuticals has entered into a licensing agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV capsid technology to develop genomic medicines for rare diseases.

Flightpath Biosciences has licensed lolamicin, a novel antibiotic developed at the University of Illinois that targets gram-negative bacteria while preserving beneficial gut microbes.

Briquilimab demonstrated remarkable efficacy in chronic spontaneous urticaria (CSU) with 89% of patients achieving complete response by week 2 in valid cohorts of the BEACON Phase 1b/2a trial.

Ascentage Pharma appointed Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance to support the company's global expansion strategy.

The Scottish Medicines Consortium has recommended Theramex's Eladynos (abaloparatide) for treating osteoporosis in postmenopausal women at very high risk of fracture through NHS Scotland.

AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.

AstraZeneca CEO Pascal Soriot has privately expressed preference to move the company's stock market listing from London to New York, according to multiple sources cited by The Times.

China's National Medical Products Administration approved the ORPATHYS-TAGRISSO combination for treating EGFR-mutated non-small cell lung cancer patients with MET amplification after disease progression on EGFR inhibitor therapy.

The FDA has approved 84 drugs in 2025 so far, marking the second-highest total for this period despite major organizational changes including 3,500 staff layoffs.

Dicot Pharma has completed enrollment and dosing of all participants in its Phase 2a clinical trial evaluating LIB-01 for erectile dysfunction treatment.